Nitric oxide (NO • ) competitively inhibits oxygen consumption by mitochondria at cytochrome c oxidase and S-nitrosates thiol proteins. We developed mitochondria-targeted S-nitrosothiols (MitoSNOs) that selectively modulate and protect mitochondrial function. The exemplar MitoSNO1, produced by covalently linking an Snitrosothiol to the lipophilic triphenylphosphonium cation, was rapidly and extensively accumulated within mitochondria, driven by the membrane potential, where it generated NO • and Snitrosated thiol proteins. MitoSNO1-induced NO • production reversibly inhibited respiration at cytochrome c oxidase and increased extracellular oxygen concentration under hypoxic conditions. MitoSNO1 also caused vasorelaxation due to its NO • generation. Infusion of MitoSNO1 during reperfusion was protective against heart ischemia-reperfusion injury, consistent with a functional modification of mitochondrial proteins, such as complex I, following S-nitrosation. These results support the idea that selectively targeting NO • donors to mitochondria is an effective strategy to reversibly modulate respiration and to protect mitochondria against ischemia-reperfusion injury.
T
here is considerable interest in the interaction of nitric oxide (NO • ) with mitochondria as it can regulate, protect, or damage mitochondria, depending on the context (1) . Physiological levels of NO
• competitively inhibit mitochondrial oxygen (O 2 ) consumption by cytochrome c oxidase (complex IV), thereby slowing respiration at low O 2 concentrations (2) . While the physiological significance of this is unclear, it may occur in vivo during hypoxia, enabling NO
• to prevent anoxia and the activation of O 2 -sensitive transcription factors (3) . The metabolism of NO
• can also lead to the S-nitrosation of thiol proteins, thereby reversibly regulating their activity (1, 4) . Although the mechanism of S-nitrosation in vivo is obscure (5) , there is evidence for the S-nitrosation of mitochondrial proteins (1, (6) (7) (8) (9) (10) . In particular, complex I, a major entry point for electrons into the respiratory chain, can be S-nitrosated (6) (7) (8) (9) (10) , which may alter its activity and thereby protect against damage during ischemia-reperfusion injury (9, 10) .
Here we report on a small molecule approach to selectively generate NO
• and S-nitrosothiols within mitochondria using mitochondria-targeted S-nitrosothiols (MitoSNOs). S-Nitrosothiols (SNOs) release NO
• slowly under the oxidizing conditions that prevail in the extracellular environment, but should release NO
• rapidly within mitochondria, probably following transnitrosation of glutathione (GSH), although the detailed mechanism of NO
• release is uncertain (5) . In addition, SNOs readily transfer NO ϩ to transnitrosates protein thiols (7) . To target SNOs to mitochondria, we attached a lipophilic triphenylphosphonium (TPP) cationic moiety, which has been used to target molecules to mitochondria both in vitro and in vivo (11) . The delocalized positive charge and lipophilic surface enables TPP cations to cross biological membranes rapidly without a requirement for a carrier protein, and to accumulate several hundredfold in energized mitochondria in vivo driven by the membrane potential (⌬) (12) . The anticipated possible modes of action of MitoSNOs are shown in Fig. 1A .
Results and Discussion
Synthesis and Stability of MitoSNO1. A mitochondria-targeted SNO (MitoSNO1) based on the stable S-nitroso-N-acetylpenicillamine (SNAP) was prepared by the S-nitrosation of the thiol precursor mito-N-acetylpenicillamine (MitoNAP) (Fig. 1B) . As a mitochondria-specific NO
• donor, MitoSNO1 should be relatively stable in aqueous solution but react rapidly with intramitochondrial thiols such as GSH to release NO • (Fig. 1 A) . Reverse-phase liquid chromatography (RP-HPLC) showed that there was negligible decay of MitoSNO1 after 1 h ( Fig. 2A) . After 21 h, MitoSNO1 had decayed by approximately 50 Ϯ 11% (mean Ϯ SEM, n ϭ 4), giving 2 new peaks by RP-HPLC (Fig.  2 A) . Electrospray mass spectrometry (ESMS) showed that 1 product was a symmetric disulfide dimer of MitoNAP (Fig. S1 ), an expected product of SNO decomposition (5) , and the other MitoNAP. The accumulation of nitrite from the breakdown of MitoSNO1 showed that MitoSNO1 decays about 2-fold faster than SNAP with half-lives of 23 Ϯ 3 h and 44 Ϯ 3 h (n ϭ 2, mean Ϯ range), respectively (Fig. 2B) . Examination of solutions of MitoSNO1 or SNAP with an NO
• electrode showed low levels of NO • (Fig. 2C) , consistent with the stability evident in Fig. 2 A and B. Addition of GSH dramatically increased NO • formation from MitoSNO1 (Fig. 2C) , probably by transnitrosation of GSH which then decays to release NO
• (5) . Confirmation that the electrode was detecting NO
• was obtained by adding oxyhemoglobin (OxyHb) to scavenge NO • (Fig. 2C) . RP-HPLC analysis showed that GSH rapidly converted MitoSNO1 to MitoNAP (Fig. 2D) , presumably by transnitrosation of GSH and reduction of any MitoNAP dimer. These results demonstrate that MitoSNO1 is relatively stable in aqueous buffer, slowly decaying to a disulfide and NO • , but that it should rapidly react with GSH inside mitochondria, probably by transnitrosation, leading to NO • production, as outlined in Fig. 1 A. Membrane Potential-Dependent Mitochondrial Uptake of MitoSNO1 and NO • Release. A significant ⌬-dependent uptake of MitoSNO1 into isolated mitochondria was observed (Fig. S2 ). Within mitochondria, MitoSNO1 was anticipated to interact with thiols such as GSH to release NO • that should then affect respiration by competitively inhibiting O 2 consumption at cytochrome c oxidase. This was demonstrated by using NO • and O 2 electrodes to measure respiration rate and NO
• concentration simultaneously (Fig. 3 ). Mitochondria were incubated with the complex I inhibitor rotenone to prevent ⌬ generation (Fig. 3A) . Addition of the respiratory substrate succinate initiated O 2 consumption and generated a ⌬, leading to a rapid increase in NO • production due to the accumulation of MitoSNO1 within mitochondria and its reaction with GSH (Fig. 3A) . The respiration rate slowed as NO • accumulated, and this inhibition was reversed by degrading NO
• with OxyHb, indicating that the respiratory inhibition was due to the reversible competition between NO • and O 2 at cytochrome c oxidase (Fig. 3A) . MitoNAP had no effect on respiration or the NO • electrode response. The amount of NO • generated by SNAP in the presence of energized mitochondria was negligible (Fig. 3B ), presumably because it was not selectively taken up by mitochondria. To explore further the ⌬-dependence of NO
• production by MitoSNO1, studies with decreased concentrations and fewer mitochondria were undertaken ( Fig. 3C and D) . The initial production of NO • from MitoSNO1 was negligible, but subsequent mitochondrial energization with succinate led to a dramatic increase in NO • production (Fig. 3C) . The build-up of NO • decreased respiration, and this was reversed by OxyHb (Fig. 3C) . Inclusion of the uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) resulted in decreased NO • production as the ⌬ was largely abolished, preventing the uptake of MitoSNO1 into mitochondria (Fig. 3D) . The decreased accumulation of NO • in the presence of FCCP still inhibited respiration, but inhibition occurred at a lower O 2 concentration (Fig.  3D) . The metabolism of MitoSNO1 by mitochondria was investigated by analyzing the amounts of MitoSNO1 and MitoNAP in the supernatant by RP-HPLC and showed that energized mitochondria rapidly converted MitoSNO1 to MitoNAP within 2-3 min. Therefore MitoSNO1 is a ⌬-dependent source of intramitochondrial NO • that can reversibly modulate mitochondrial O 2 consumption, particularly at low O 2 concentrations.
Uptake of MitoSNO1 by Cells Leads to NO • Generation and Respiratory
Inhibition. The effect of MitoSNO1 on respiration by Jurkat cells was measured using an O 2 electrode (Fig. 4) . There was no initial effect on respiration rate after addition of MitoSNO1, but as the cells consumed more O 2 , the respiration rate decreased and approached zero even though there was still O 2 remaining (Fig.  4A ). This inhibition was reversible and was due to NO • , as degradation with OxyHb restored the maximal respiration rate and allowed the O 2 concentration to reduce to zero (Fig. 4A) . At low O 2 concentrations, the NO
• generated by MitoSNO1 prevented mitochondrial oxygen consumption almost entirely and maintained a low O 2 concentration. This is illustrated in the expanded O 2 electrode trace in Fig. 4A , which shows that addition of OxyHb restores respiration by degrading NO • . In contrast, neither MitoNAP (Fig. 4B) nor SNAP (Fig. 4C ) affected respiration. Addition of the uncoupler FCCP before MitoSNO1 prevented the inhibition of respiration (Fig. 4D) . The effective K m of cytochrome c oxidase for O 2 is very low (Ͻ 1 M) (13), illustrated by the sharp transition from maximal O 2 consumption to zero respiration in Fig. 4B . This contrasts with the situation in the presence of MitoSNO1 (Fig. 4A) where there is a gradual decline in O 2 consumption rate. These findings are consistent with the ⌬-dependent uptake of MitoSNO1 into mitochondria within cells facilitating NO • release, which slows respiration through the competitive inhibition between NO • and O 2 at cytochrome c oxidase and becomes more effective as the O 2 concentration decreases. We next determined whether the reversible inhibition of cytochrome c oxidase by NO • from MitoSNO1 could increase O 2 bioavailability during hypoxic conditions. HeLa cells were maintained at 1% O 2 for 60 min and then the effects of a further 30-min incubation with MitoSNO1, MitoNAP, or the mitochondrial inhibitor myxathiazol on extracellular pO 2 was assessed by fluorescence quenching oximetry (Fig. 4E ). MitoSNO1 and myxathiazol both increased extracellular O 2 during hypoxia compared with controls, while MitoNAP had no effect (Fig. 4E) . This demonstrates that NO • production by MitoSNO1 within the mitochondria of hypoxic cells can slow respiration sufficiently to modulate cytosolic O 2 concentration.
S-Nitrosation of Mitochondrial Protein Thiols by MitoSNO1.
To evaluate the S-nitrosation of mitochondrial thiol proteins by MitoSNO1 (Fig. 1 A) , MitoSNO1 was incubated with isolated mitochondria, and a sensitive chemiluminescence assay was used to measure SNOs (14) . S-nitrosation of mitochondrial proteins by MitoSNO1 was found to peak over 2-3 min and then gradually decline (Fig. 5A) , consistent with the metabolism of MitoSNO1 seen in Fig. 3 . Incubation of mitochondria with MitoSNO1 for 2.5 min showed extensive, concentration-dependent Snitrosation of proteins that was largely blocked by abolishing the ⌬ with the uncoupler FCCP (Fig. 5B) . In contrast, SNAP, even at 50 M, led to negligible S-nitrosation (Fig. 5B) . Blocking protein thiols with the alkylating agent N-ethyl maleimide (NEM) prevented S-nitrosation by MitoSNO1 (Fig. 5B) . Incubations with MitoSNO1 in the absence of free NO • , achieved by excess OxyHb, still led to extensive mitochondrial S-nitrosation (Fig. S3) . Incubation of mitochondria with 500 M of 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene (Deta-NONOate), which generates a 5-to 10-fold greater NO • concentration than 5 M MitoSNO1 (Fig. S4A ), but does not transnitrosate thiols (7) , gave approximately 20 pmol SNO/mg protein, around 30-fold less than that caused by 5 M MitoSNO1 (Fig. S4B) . Thus the contribution of free NO
• to S-nitrosation by MitoSNO1 is minor. Therefore MitoSNO1 leads to the extensive Snitrosation of mitochondrial thiol proteins following its ⌬-dependent uptake into the matrix, and this S-nitrosation is predominantly due to the direct transfer of NO ϩ from MitoSNO1 to thiolates within the matrix.
Incubation of C2C12 cells with MitoSNO1 led to protein S-nitrosation that peaked after 5-10 min (Fig. S5) . The extent of S-nitrosation by MitoSNO1 after 5 min was considerably greater than that by SNAP and was decreased by the uncoupler FCCP (Fig. 5C ). When a mitochondria-enriched fraction was isolated from cells that had been incubated with MitoSNO1 the mitochondrial proteins were extensively S-nitrosated and this was decreased by abolishing the ⌬ with FCCP (Fig. 5D ). These data demonstrate the accumulation of MitoSNO1 within mitochondria inside cells where it selectively S-nitrosates thiol proteins. The interaction of MitoSNO1 with mitochondrial thiol proteins may lead to other modifications, such as disulfide formation, glutathionylation, sulfenylation, or sulfenylamide formation, in addition to persistent S-nitrosation (7) . To assess these, the content of reactive, solvent-exposed thiols on native mitochondrial proteins was measured. Under control conditions, there were 43.2 Ϯ 3.8 nmol thiols/mg protein, and after incubation with 5 M MitoSNO1 for 5 min, this did not change significantly (46.7 Ϯ 9.6; means Ϯ SEM, n ϭ 3). This is consistent with the finding that the extent of mitochondrial protein Snitrosation by 5 M MitoSNO1 (Ϸ500 pmol SNO/mg protein; Fig. 5 ) was only approximately 1% of the total protein thiols available. Incubation of mitochondria with 10 M MitoSNO1 for 10 min showed no loss of GSH or accumulation of GSSG. While there was a small amount of MitoSNO1 binding to thiol proteins through disulfide bonds (Fig. S6) , protein-glutathione mixed disulfides in mitochondria incubated with MitoSNO1 were not detectable (Fig. S7) . To visualize S-nitrosated mitochondrial proteins, free thiols are first alkylated, then S-nitrosothiols are selectively degraded with ascorbate and copper to generate an exposed thiol that is labeled with a fluorescently-tagged Cy3 maleimide (15) . This technique showed that exposure of liver (Fig. 5E) or heart (Fig. 5F ) mitochondria to MitoSNO1 led to the S-nitrosation of a large number of different proteins. The thiol oxidant diamide did not label proteins, indicating that this technique is selective for SNOs over other thiol modifications. To summarize, MitoSNO1 does not lead to bulk changes in free protein thiol content or the GSH pool, but instead causes the S-nitrosation of a small proportion of mitochondrial protein thiols that persists in the presence of a reduced mitochondrial glutathione pool, indicating that the local environments of the particular cysteine residues affected may help stabilize these S-nitrosothiols (4).
Effect of MitoSNO1 on Complex I Activity and S-nitrosation.
Complex I, the major entry point for electrons into the respiratory chain, can be S-nitrosated, and this correlates with potentially important alterations to its activity (6-10). MitoSNO1 inhibited respiration by about 30% on the complex I-linked substrates glutamate/malate, but had little effect on respiration with the complex II substrate succinate (Fig. 6A) . As this inhibition occurred in the presence of high O 2 concentrations, did not vary with the O 2 concentration, and did not affect respiration on succinate, it was not due to NO • inhibition at cytochrome c oxidase (Fig. 3) . MitoSNO1 is either inhibiting NADH oxidation by complex I or affecting NADH supply. To distinguish between these possibilities, we investigated respiration by mitochondrial membranes that directly oxidize both succinate and NADH (Fig.  6B) . Results showed that MitoSNO1 inhibited NADH respiration by about 35% while succinate was unaffected (Fig. 6B) , strongly pointing to a specific effect of MitoSNO1 on complex I.
As the inhibition of complex I by MitoSNO1 in mitochondria occurred in the presence of a reduced GSH pool, we assessed the effect of GSH on complex I inhibition and S-nitrosation by MitoSNO1. Incubating MitoSNO1-treated membranes with 1 mM GSH for 10-15 min did not reverse the inhibition of NADH respiration. Incubation of membranes with MitoSNO1 under the conditions described in Fig. 6B led to the formation of 4.8 Ϯ 0.9 nmol SNOs/mg protein (mean Ϯ SD, n ϭ 4), and GSH treatment only decreased the SNO content by approximately 50%. To confirm that complex I was S-nitrosated, we incubated membranes with MitoSNO1 for 5 min and then selectively tagged S-nitrosothiols with Cy3-maleimide (15) . Complex I was then isolated by blue native polyacrylamide gel electrophoresis (BN-PAGE) and showed that complex I was S-nitrosated (Fig.  6C) . Incubation of membranes with 1 mM GSH for 15 min did not reverse this complex I S-nitrosation (Fig. 6D) . Thus, the inhibition of complex I activity on MitoSNO1 treatment may result from S-nitrosation that is relatively resistant to reversal by GSH. Therefore, MitoSNO1 persistently S-nitrosates complex I, and the continued inhibition of complex I by MitoSNO1, even in the presence of GSH, correlates with its S-nitrosation. 
subsequent NO
• release may make MitoSNO1 a potent vasodilator (Fig. 1 A) . This was evaluated by determining whether MitoSNO1 could relax the smooth muscle in blood vessel walls. Sections of rat thoracic aorta in a myograph were precontracted, and then cumulative amounts of MitoSNO1 were added (Fig.  7A ). This showed that MitoSNO1 was a vasodilator, and that pretreating MitoSNO1 to degrade its SNO moiety rendered it ineffective (Fig. 7A) . In this assay, MitoSNO1 was a more potent vasodilator than SNAP (Fig. 7B) . MitoSNO1 was also an effective vasodilator in endothelium-denuded rat resistance mesenteric arteries (Fig. S8 ). These data demonstrate MitoSNO1 is an effective endothelium-independent vasodilator acting via NO • release within tissues. As TPP compounds are rapidly taken up from the circulation by the heart following i.v. injection, this may indicate more rapid ways of targeting pathologies such as angina, while also avoiding the problem of nitrate tolerance that impedes the use of nitroglycerin.
MitoSNO1 Protects Against Cardiac Ischemia-reperfusion Injury.
There is considerable evidence pointing to mitochondrial damage during the reperfusion phase of cardiac ischemiareperfusion (I/R) injury (6, 9, 10). This damage can be decreased by ischemic preconditioning (IPC), whereby previous exposure to short periods of I/R protects against subsequent I/R injury (6, 9, 10) . While the nature of the protection afforded by IPC remains obscure, mitochondrial NO
• and NO 2 Ϫ metabolism may play a role, perhaps through the S-nitrosation of mitochondrial proteins, particularly complex I, protecting mitochondrial function on reperfusion (9, 10, 16). As MitoSNO1 is rapidly taken up by mitochondria within cells where it S-nitrosates proteins, including complex I (Figs. 5 and 6 ), it may also protect heart mitochondria from I/R damage. When mouse hearts were Langendorff perfused and subjected to 25 min of global normothermic ischemia followed by 1 h of normoxic reperfusion, there was extensive damage, as indicated by the decrease in function (rate pressure product, RPP) (Fig. 7C) and by the large infarcted area (Fig. 7D) . When MitoSNO1 was perfused into the heart during reperfusion, there was significantly less damage, as indicated by the better recovery of function (Fig. 7C ) and the decrease in infarct size (Fig. 7D) . Infusion of MitoNAP during the reperfusion phase was far less protective than MitoSNO1 (Fig. 7C and D) . A small degree of protection was also observed when MitoSNO1 was delivered before the I/R injury, similar to that observed with the parent compound MitoNAP (Fig. S9) . The rapid metabolism of MitoSNO1 in cells may be such that Bovine heart mitochondrial membranes were incubated and processed as in (C) except that after incubation Ϯ MitoSNO1 the membranes were incubated Ϯ 1 mM GSH for 15 min. 
